Corifollitropin Alfa (Elonva)
Overview
Corifollitropin alfa is a recombinant long-acting FSH analogue created by fusing the C-terminal peptide of the hCG beta subunit to the FSH beta chain. This structural modification extends the elimination half-life to approximately 70 hours, enabling a single injection to sustain follicular stimulation for seven days. The agent is designed to simplify controlled ovarian stimulation protocols by replacing the first week of daily FSH injections in IVF cycles.
Key Research Findings
FDA approval was granted in 2014 following the Ensure and Engage trials, which demonstrated non-inferiority to daily recombinant FSH in oocyte yield and ongoing pregnancy rates. Studies published in The Lancet and Fertility and Sterility confirmed reduced injection burden with comparable safety profiles. The agent is now approved in multiple countries for use in women undergoing ART.
Subcutaneous injection
FDA Approved
Interested in Corifollitropin Alfa (Elonva)?
Find a verified provider experienced with Corifollitropin Alfa (Elonva) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Corifollitropin Alfa (Elonva) ProviderRelated Peptides
Leuprolide (Lupron)
FDA ApprovedA synthetic nonapeptide GnRH agonist approximately 15-fold more potent than native GnRH. After an initial stimulatory phase (flare effect) lasting 1-2 weeks, chronic leuprolide administration downregulates pituitary GnRH receptors, resulting in profound suppression of LH, FSH, and downstream sex steroids. This chemical castration effect is exploited in treating hormone-sensitive cancers, endometriosis, and precocious puberty.
Goserelin (Zoladex)
FDA ApprovedA synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug release over 1 or 3 months. Like other GnRH agonists, goserelin initially stimulates and then suppresses the HPG axis, reducing sex hormone production to castrate or postmenopausal levels. The implant formulation eliminates the need for repeated injections and ensures compliance.
Cetrorelix (Cetrotide)
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively blocks pituitary GnRH receptors, producing immediate and dose-dependent suppression of LH and FSH without the initial flare effect seen with GnRH agonists. Cetrorelix prevents premature LH surges during controlled ovarian stimulation in IVF, allowing precise timing of oocyte maturation and retrieval.
Ganirelix
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors on pituitary gonadotroph cells. Ganirelix rapidly suppresses LH secretion within hours of administration, preventing premature ovulation during assisted reproductive technology (ART) cycles. Its mechanism provides immediate suppression without the flare phase associated with GnRH agonists.